The US Patent and Trademark Office’s (USPTO’s) Patent Trial and Appeal Board (PTAB) has cleared the path for generics of Janssen’s Zytiga (abiraterone acetate) blockbuster to reach the market as early as September this year, after invalidating a key patent shielding the prostate-cancer treatment.
The US Patent and Trademark Office’s (USPTO’s) Patent Trial and Appeal Board (PTAB) has cleared the path for generics of Janssen’s Zytiga (abiraterone acetate) blockbuster to reach the market as early as September this year, after invalidating a key patent shielding the prostate-cancer treatment.
After instituting inter partes reviews of claims 1-20 in US composition and method-of-use patent 8,822,438, the PTAB issued three final...
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
